Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893839 | 1.00 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8731919 | 0.99 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8073453 | 0.93 | LTB4R (0.87) | LTB4R | |
| SCHEMBL8065708 | 0.93 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8075661 | 0.92 | LTB4R (0.87) | LTB4R | |
| SCHEMBL13696782 | 0.92 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8065585 | 0.92 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8066017 | 0.92 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8862134 | 0.91 | LTB4R (0.84) | LTB4R | |
| SCHEMBL8862056 | 0.91 | LTB4R (0.84) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250127793-A1 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | REVOPSIS HOLDINGS, LLC | 2025-04-24 | — | — | US | disclosed |
| US-12269801-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250002595-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX INC (US) | 2025-01-02 | — | — | US | disclosed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-1326605-A4 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | UNIV CREIGHTON (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6617345-B1 | Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides | G.D. SEARLE & CO. | 2003-09-09 | — | — | US | disclosed |
| EP-1326605-A1 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | CREIGHTON UNIVERSITY (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2001085166-A1 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | CREIGHTON UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885 |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR1, FOLR2, DHFR | LTB4R 1331/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885 |
| US-12269801-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | LTB4R 2470/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885 |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | LTB4R 2470/4885 |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | LTB4R 1/4885 |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | LTB4R 3875/4885 |
| US-20250002595-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | LTB4R 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.